Starting July 1, 2026, the Centers for Medicare & Medicaid Services (CMS) launched a short-term demonstration program called the Medicare GLP-1 Bridge. It gives eligible Part D beneficiaries access to certain GLP-1 drugs for weight loss at a predictable monthly cost. This article explains the basics of the program, what it covers, who qualifies, and how it differs from standard Part D coverage. What Is the Medicare GLP-1 Bridge Program? The Medicare GLP-1 Bridge is a temporary demonstration program run by CMS. It runs from July 1, 2026, through December 31, 2027. The program operates outside the standard Medicare Part D benefit, using a central processor managed by CMS to handle prior authorization, claims, and payments. Part D sponsors do not need to opt in for their beneficiaries to access Bridge drugs. The program was created to fill a gap after the BALANCE Model, originally planned for 2027, was delayed indefinitely. Which Drugs Are Covered? The Bridge covers a limited set of G...